Titlerug treatment of the overweight patient.
Authors:Bray GA, Ryan DH.
Resource: Gastroenterology. 2007 May;132:2239-52
Three medications with approval for long-term use in the treatment of obesity are currently available in the United States. Sibutramine (U.S. Food and Drug Administration [FDA] approved in 1997), orlistat (FDA approved in 1999), and rimonabant (available in Europe and given FDA approvable status in 2006 and expected to be marketed in 2007) represent modern approaches to medications used adjunctively for weight management. As demonstrated in large clinical trials of 2 to 4 years' duration, these medications significantly increase weight loss compared with placebo; weight loss with these drugs reaches a nadir between 20 and 28 weeks; weight loss, averaged 8%-10%, with the placebo contributing 4%-6% of that. Weight maintenance is demonstrated as long as adherence to medication continues. All medications have side effects that need to be considered. For sibutramine, there is a rise in blood pressure and heart rate that may require discontinuation of the drug in a small percent of patients. For orlistat, steatorrhea produces the principal gastrointestinal side effects. Rimonabant appears to have a favorable safety and tolerability profile. Nausea and gastrointestinal symptoms are the chief tolerability issue, but they are usually self-limited. In addition there are several drugs and drug combinations in phase 2 or phase 2 trials that will be reported on in the coming years.
PMID: 17498515 [PubMed - in process]
本人已认领该文编译，48小时后若未提交译文，请其他战友自由认领
Title：Drug treatment of the overweight patient
题目：肥胖的药物治疗
Authors:Bray GA, Ryan DH.
作者：Bray GA, Ryan DH.
Resource: Gastroenterology. 2007 May;132:2239-52
来源：胃肠病学.2007 May;132:2239-52
Three medications with approval for long-term use in the treatment of obesity are currently available in the United States. Sibutramine (U.S. Food and Drug Administration [FDA] approved in 1997), orlistat (FDA approved in 1999), and rimonabant (available in Europe and given FDA approvable status in 2006 and expected to be marketed in 2007) represent modern approaches to medications used adjunctively for weight management.
现在3种用于肥胖长期治疗的药物已经在美国上市。西布曲明（1997年获美国食品药品管理局[FDA]认可）、奥利司他（1999年获FDA认可）和利莫那班（在欧洲已经上市，2006年获FDA认可，预计2007在美国上市）是肥胖治疗种3种具有代表性的辅助药物。
As demonstrated in large clinical trials of 2 to 4 years' duration, these medications significantly increase weight loss compared with placebo; weight loss with these drugs reaches a nadir between 20 and 28 weeks; weight loss, averaged 8%-10%, with the placebo contributing 4%-6% of that.
为期2-4年的大规模临床实验显示，这些药物与安慰剂相比可明显使体重减轻；这些药物引起的体重减轻在20-28周达到最低；可使体重平均降低8％-10％，而安慰剂仅为4％-6％。
Weight maintenance is demonstrated as long as adherence to medication continues. All medications have side effects that need to be considered. For sibutramine, there is a rise in blood pressure and heart rate that may require discontinuation of the drug in a small percent of patients.
实验结果证明，只要坚持服药，体重就可以维持，但必须考虑到所有药物的副作用。以西布曲明为例，它可引起血压和心率升高，因此少部分病人需停药一段时间。
For orlistat, steatorrhea produces the principal gastrointestinal side effects. Rimonabant appears to have a favorable safety and tolerability profile. Nausea and gastrointestinal symptoms are the chief tolerability issue, but they are usually self-limited. In addition there are several drugs and drug combinations in phase 2 or phase 2 trials that will be reported on in the coming years.
对奥利司他而言，脂肪痢是主要的胃肠道副反应。利莫那班似乎在安全性和耐受性方面更好。耐受性主要与恶心和胃肠道症状有关，但它们常常因人而异。未来几年还将有另外几种处于2期或2期实验的药物或合剂被报道。
编译后：约350字
Bray GA及其同事对肥胖的药物治疗进行了研究，结果发表在2007.5的《胃肠病学》。现在3种用于肥胖长期治疗的药物已经在美国上市。西布曲明（1997年获美国食品药品管理局[FDA]认可）、奥利司他（1999年获FDA认可）和利
莫那班（在欧洲已经上市，2006年获FDA认可，预计2007在美国上市）是肥胖治疗种3种具有代表性的辅助药物。研究人员在为期2-4年的大规模临床实验中发现，这些药物与安慰剂相比可明显使体重减轻；这些药物引起的体重减轻在20-28周达到最低；可使体重平均降低8％-10％，而安慰剂仅为4％-6％。实验结果证明，只要坚持服药，体重就可以维持，但必须考虑到所有药物的副作用。以西布曲明为例，它可引起血压和心率升高，因此少部分
病人需停药一段时间。对奥利司他而言，脂肪痢是主要的胃肠道副反应。利莫那班似乎在安全性和耐受性方面更好。耐受性主要与恶心和胃肠道症状有关，但它们常常因人而异。未来几年还将有另外几种处于2期或2期实验的药物或合剂被报道。
